Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
MedImmune LLC
AstraZeneca
CytoDyn, Inc.
Mayo Clinic
Dana-Farber Cancer Institute
Fundación GECP
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb
Sanofi
BeiGene
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Gilead Sciences
BeiGene
Eisai Inc.
Sellas Life Sciences Group
ImaginAb, Inc.
BioMed Valley Discoveries, Inc
Hoosier Cancer Research Network
Memorial Sloan Kettering Cancer Center
Canadian Cancer Trials Group
Verastem, Inc.
Debiopharm International SA
Dana-Farber Cancer Institute
University of Chicago
Merck Sharp & Dohme LLC
Baptist Health South Florida
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
Bayer
PrECOG, LLC.
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
PharmaMar
M.D. Anderson Cancer Center
Baylor College of Medicine
Morphotek
Eli Lilly and Company
Virginia Commonwealth University
Barbara Ann Karmanos Cancer Institute
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Nektar Therapeutics
Hoffmann-La Roche